Cargando…

Circulating tumor cells in newly diagnosed inflammatory breast cancer

INTRODUCTION: Circulating tumor cells (CTCs) are an independent prognostic factor for progression-free survival (PFS) and overall survival (OS) in patients with metastatic breast cancer. Inflammatory breast cancer (IBC) is one of the most aggressive forms of breast cancer. The prognostic value of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mego, Michal, Giordano, Antonio, De Giorgi, Ugo, Masuda, Hiroko, Hsu, Limin, Giuliano, Mario, Fouad, Tamer M, Dawood, Shaheenah, Ueno, Naoto T, Valero, Vicente, Andreopoulou, Eleni, Alvarez, Ricardo H, Woodward, Wendy A, Hortobagyi, Gabriel N, Cristofanilli, Massimo, Reuben, James M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318180/
https://www.ncbi.nlm.nih.gov/pubmed/25572591
http://dx.doi.org/10.1186/s13058-014-0507-6
_version_ 1782355817128787968
author Mego, Michal
Giordano, Antonio
De Giorgi, Ugo
Masuda, Hiroko
Hsu, Limin
Giuliano, Mario
Fouad, Tamer M
Dawood, Shaheenah
Ueno, Naoto T
Valero, Vicente
Andreopoulou, Eleni
Alvarez, Ricardo H
Woodward, Wendy A
Hortobagyi, Gabriel N
Cristofanilli, Massimo
Reuben, James M
author_facet Mego, Michal
Giordano, Antonio
De Giorgi, Ugo
Masuda, Hiroko
Hsu, Limin
Giuliano, Mario
Fouad, Tamer M
Dawood, Shaheenah
Ueno, Naoto T
Valero, Vicente
Andreopoulou, Eleni
Alvarez, Ricardo H
Woodward, Wendy A
Hortobagyi, Gabriel N
Cristofanilli, Massimo
Reuben, James M
author_sort Mego, Michal
collection PubMed
description INTRODUCTION: Circulating tumor cells (CTCs) are an independent prognostic factor for progression-free survival (PFS) and overall survival (OS) in patients with metastatic breast cancer. Inflammatory breast cancer (IBC) is one of the most aggressive forms of breast cancer. The prognostic value of a CTC count in newly diagnosed IBC has not been established. The aim of this study was to assess the prognostic value of a baseline CTC count in patients with newly diagnosed IBC. METHODS: This retrospective study included 147 patients with newly diagnosed IBC (77 with locally advanced and 70 with metastatic IBC) treated with neoadjuvant therapy or first-line chemotherapy during the period from January 2004 through December 2012 at The University of Texas MD Anderson Cancer Center. CTCs were detected and enumerated by using the CellSearch system before patients were started with chemotherapy. RESULTS: The proportion of patients with ≥1 CTC was lower among patients with stage III than among patients with metastatic IBC (54.5% versus 84.3%; P = 0.0002); the proportion of patients with ≥5 CTCs was also lower for stage III than for metastatic IBC (19.5% versus 47.1%; P = 0.0004). Patients with fewer than five CTCs had significantly better progression-free survival (PFS) (hazard ratio (HR) = 0.60; P = 0.02) and overall survival (HR = 0.59; P = 0.03) than patients with five or more CTCs. Among patients with stage III IBC, there was a nonsignificant difference in PFS (HR = 0.66; 95% confidence interval (CI), 0.31 to 1.39; P = 0.29) and OS (HR = 0.54; 95% CI, 0.24 to 1.26; P = 0.48) in patients with no CTCs compared with patients with one or more CTCs. In multivariate analysis, CTC was prognostic for PFS and OS independent of clinical stage. CONCLUSIONS: CTCs can be detected in a large proportion of patients with newly diagnosed IBC and are a strong predictor of worse prognosis in patients with newly diagnosed IBC.
format Online
Article
Text
id pubmed-4318180
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43181802015-02-06 Circulating tumor cells in newly diagnosed inflammatory breast cancer Mego, Michal Giordano, Antonio De Giorgi, Ugo Masuda, Hiroko Hsu, Limin Giuliano, Mario Fouad, Tamer M Dawood, Shaheenah Ueno, Naoto T Valero, Vicente Andreopoulou, Eleni Alvarez, Ricardo H Woodward, Wendy A Hortobagyi, Gabriel N Cristofanilli, Massimo Reuben, James M Breast Cancer Res Research Article INTRODUCTION: Circulating tumor cells (CTCs) are an independent prognostic factor for progression-free survival (PFS) and overall survival (OS) in patients with metastatic breast cancer. Inflammatory breast cancer (IBC) is one of the most aggressive forms of breast cancer. The prognostic value of a CTC count in newly diagnosed IBC has not been established. The aim of this study was to assess the prognostic value of a baseline CTC count in patients with newly diagnosed IBC. METHODS: This retrospective study included 147 patients with newly diagnosed IBC (77 with locally advanced and 70 with metastatic IBC) treated with neoadjuvant therapy or first-line chemotherapy during the period from January 2004 through December 2012 at The University of Texas MD Anderson Cancer Center. CTCs were detected and enumerated by using the CellSearch system before patients were started with chemotherapy. RESULTS: The proportion of patients with ≥1 CTC was lower among patients with stage III than among patients with metastatic IBC (54.5% versus 84.3%; P = 0.0002); the proportion of patients with ≥5 CTCs was also lower for stage III than for metastatic IBC (19.5% versus 47.1%; P = 0.0004). Patients with fewer than five CTCs had significantly better progression-free survival (PFS) (hazard ratio (HR) = 0.60; P = 0.02) and overall survival (HR = 0.59; P = 0.03) than patients with five or more CTCs. Among patients with stage III IBC, there was a nonsignificant difference in PFS (HR = 0.66; 95% confidence interval (CI), 0.31 to 1.39; P = 0.29) and OS (HR = 0.54; 95% CI, 0.24 to 1.26; P = 0.48) in patients with no CTCs compared with patients with one or more CTCs. In multivariate analysis, CTC was prognostic for PFS and OS independent of clinical stage. CONCLUSIONS: CTCs can be detected in a large proportion of patients with newly diagnosed IBC and are a strong predictor of worse prognosis in patients with newly diagnosed IBC. BioMed Central 2015-01-09 2015 /pmc/articles/PMC4318180/ /pubmed/25572591 http://dx.doi.org/10.1186/s13058-014-0507-6 Text en © Mego et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Mego, Michal
Giordano, Antonio
De Giorgi, Ugo
Masuda, Hiroko
Hsu, Limin
Giuliano, Mario
Fouad, Tamer M
Dawood, Shaheenah
Ueno, Naoto T
Valero, Vicente
Andreopoulou, Eleni
Alvarez, Ricardo H
Woodward, Wendy A
Hortobagyi, Gabriel N
Cristofanilli, Massimo
Reuben, James M
Circulating tumor cells in newly diagnosed inflammatory breast cancer
title Circulating tumor cells in newly diagnosed inflammatory breast cancer
title_full Circulating tumor cells in newly diagnosed inflammatory breast cancer
title_fullStr Circulating tumor cells in newly diagnosed inflammatory breast cancer
title_full_unstemmed Circulating tumor cells in newly diagnosed inflammatory breast cancer
title_short Circulating tumor cells in newly diagnosed inflammatory breast cancer
title_sort circulating tumor cells in newly diagnosed inflammatory breast cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318180/
https://www.ncbi.nlm.nih.gov/pubmed/25572591
http://dx.doi.org/10.1186/s13058-014-0507-6
work_keys_str_mv AT megomichal circulatingtumorcellsinnewlydiagnosedinflammatorybreastcancer
AT giordanoantonio circulatingtumorcellsinnewlydiagnosedinflammatorybreastcancer
AT degiorgiugo circulatingtumorcellsinnewlydiagnosedinflammatorybreastcancer
AT masudahiroko circulatingtumorcellsinnewlydiagnosedinflammatorybreastcancer
AT hsulimin circulatingtumorcellsinnewlydiagnosedinflammatorybreastcancer
AT giulianomario circulatingtumorcellsinnewlydiagnosedinflammatorybreastcancer
AT fouadtamerm circulatingtumorcellsinnewlydiagnosedinflammatorybreastcancer
AT dawoodshaheenah circulatingtumorcellsinnewlydiagnosedinflammatorybreastcancer
AT uenonaotot circulatingtumorcellsinnewlydiagnosedinflammatorybreastcancer
AT valerovicente circulatingtumorcellsinnewlydiagnosedinflammatorybreastcancer
AT andreopouloueleni circulatingtumorcellsinnewlydiagnosedinflammatorybreastcancer
AT alvarezricardoh circulatingtumorcellsinnewlydiagnosedinflammatorybreastcancer
AT woodwardwendya circulatingtumorcellsinnewlydiagnosedinflammatorybreastcancer
AT hortobagyigabrieln circulatingtumorcellsinnewlydiagnosedinflammatorybreastcancer
AT cristofanillimassimo circulatingtumorcellsinnewlydiagnosedinflammatorybreastcancer
AT reubenjamesm circulatingtumorcellsinnewlydiagnosedinflammatorybreastcancer